Francesco Zaja

Summary

Country: Italy

Publications

  1. doi request reprint No evidences for B-cell clonality by spectratyping analysis in patients with idiopathic thrombocytopenic purpura undergoing rituximab therapy
    Eleonora Toffoletti
    Haematologica 93:795-6. 2008
  2. pmc Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy
    Luca Arcaini
    Department of Hematology Oncology, University of Pavia, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
    Clin Dev Immunol 2012:638185. 2012
  3. doi request reprint Bendamustine salvage therapy for T cell neoplasms
    Francesco Zaja
    Clinica Ematologica, DISM, Azienda Ospedaliero Universitaria S M Misericordia, p le S Maria Misericordia 15, 33100, Udine, Italy
    Ann Hematol 92:1249-54. 2013
  4. doi request reprint Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia
    Francesco Zaja
    Clinica Ematologica, Centro Trapianti e Terapie Cellulari Carlo Melzi, DISM, Azienda Ospedaliero Universitaria S M Misericordia, Udine, Italy
    Am J Hematol 87:886-9. 2012
  5. doi request reprint Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab
    Francesco Zaja
    Clinica Ematologica, Centro Trapianti e Terapie Cellulari Carlo Melzi DISM, Azienda Ospedaliera Universitaria S Maria Misericordia, Udine, Italy
    Am J Hematol 87:321-3. 2012
  6. pmc Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers
    Francesco Zaja
    Clinica Ematologica, Centro Trapianti e Terapie Cellulari Carlo Melzi, Azienda Ospedaliero Universitaria S M Misericordia, p le S Maria Misericordia 15, 33100 Udine, Italy
    Haematologica 97:416-22. 2012
  7. doi request reprint Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura
    Francesco Zaja
    Clinica Ematologica, Azienda Ospedaliera Universitaria, piazza S Maria della Misericordia, 33100 Udine, Italy
    Haematologica 93:930-3. 2008
  8. doi request reprint Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia
    Francesco Zaja
    Department of Hematology Dipartimento Ricerche Mediche Morfologiche, Azienda Ospedaliero Universitaria S Maria della Misericordia, Udine, Italy
    Blood 115:2755-62. 2010
  9. doi request reprint Low-dose rituximab in adult patients with primary immune thrombocytopenia
    Francesco Zaja
    Clinica Ematologica, DIRM, Azienda Ospedaliero Universitaria S Maria Misericordia, Udine, Italy
    Eur J Haematol 85:329-34. 2010
  10. doi request reprint Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results
    Marta Medeot
    Clinica Ematologica, DIRM, University of Udine, Udine, Italy
    Eur J Haematol 81:165-9. 2008

Collaborators

Detail Information

Publications27

  1. doi request reprint No evidences for B-cell clonality by spectratyping analysis in patients with idiopathic thrombocytopenic purpura undergoing rituximab therapy
    Eleonora Toffoletti
    Haematologica 93:795-6. 2008
  2. pmc Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy
    Luca Arcaini
    Department of Hematology Oncology, University of Pavia, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
    Clin Dev Immunol 2012:638185. 2012
    ....
  3. doi request reprint Bendamustine salvage therapy for T cell neoplasms
    Francesco Zaja
    Clinica Ematologica, DISM, Azienda Ospedaliero Universitaria S M Misericordia, p le S Maria Misericordia 15, 33100, Udine, Italy
    Ann Hematol 92:1249-54. 2013
    ..At a median follow-up of 6 months (range 1-18), 13 patients are alive and 7 patients died all because of lymphoma progression. Bendamustine deserves further investigation in patients with T cell neoplasms...
  4. doi request reprint Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia
    Francesco Zaja
    Clinica Ematologica, Centro Trapianti e Terapie Cellulari Carlo Melzi, DISM, Azienda Ospedaliero Universitaria S M Misericordia, Udine, Italy
    Am J Hematol 87:886-9. 2012
    ..Rituximab SD appears a safe and active agent allowing in nearly 40% of cases to achieve long-term response and splenectomy sparing effect...
  5. doi request reprint Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab
    Francesco Zaja
    Clinica Ematologica, Centro Trapianti e Terapie Cellulari Carlo Melzi DISM, Azienda Ospedaliera Universitaria S Maria Misericordia, Udine, Italy
    Am J Hematol 87:321-3. 2012
    ..These results highlight the therapeutic activity and good safety profile of dapsone in patients with ITP who previously failed rituximab treatment...
  6. pmc Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers
    Francesco Zaja
    Clinica Ematologica, Centro Trapianti e Terapie Cellulari Carlo Melzi, Azienda Ospedaliero Universitaria S M Misericordia, p le S Maria Misericordia 15, 33100 Udine, Italy
    Haematologica 97:416-22. 2012
    ..Preclinical studies have highlighted the activity of lenalidomide in mantle cell lymphoma and its anti-proliferative synergy with dexamethasone...
  7. doi request reprint Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura
    Francesco Zaja
    Clinica Ematologica, Azienda Ospedaliera Universitaria, piazza S Maria della Misericordia, 33100 Udine, Italy
    Haematologica 93:930-3. 2008
    ..After a median follow-up of 11 months (range 3-18), 7/21 (33%) patients relapsed and 3 needed further treatments. In patients with idiopathic thrombocytopenic purpura, lower dose rituximab seems to show similar activity to standard dose...
  8. doi request reprint Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia
    Francesco Zaja
    Department of Hematology Dipartimento Ricerche Mediche Morfologiche, Azienda Ospedaliero Universitaria S Maria della Misericordia, Udine, Italy
    Blood 115:2755-62. 2010
    ..Thus, combination therapy may represent an effective treatment option before splenectomy. This study is registered at http://clinicaltrials.gov as NCT00770562...
  9. doi request reprint Low-dose rituximab in adult patients with primary immune thrombocytopenia
    Francesco Zaja
    Clinica Ematologica, DIRM, Azienda Ospedaliero Universitaria S Maria Misericordia, Udine, Italy
    Eur J Haematol 85:329-34. 2010
    ..In this setting, several evidences support the possible use of lower doses of rituximab. Objectives: To investigate the activity of low-dose rituximab as salvage therapy in previously treated symptomatic ITP...
  10. doi request reprint Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results
    Marta Medeot
    Clinica Ematologica, DIRM, University of Udine, Udine, Italy
    Eur J Haematol 81:165-9. 2008
    ..To evaluate the long-term activity and toxicity profile of rituximab in adult patients with idiopathic immune thrombocytopenic purpura (ITP)...
  11. ncbi request reprint Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases
    Francesco Zaja
    Clinica Ematologica, Policlinico Universitario, P zza S M Misericordia, 33100 Udine, Italy
    Leuk Lymphoma 44:1951-5. 2003
    ..Retreatment of both patients with IT and ADN was effective. Rituximab may be an alternative agent for the treatment CLL-associated autoimmune diseases...
  12. ncbi request reprint B-cell compartment as the selective target for the treatment of immune thrombocytopenias
    Francesco Zaja
    Clinica Ematologica, Policlinico Universitario, P zza S Maria della Misericordia, 33100 Udine, Italy
    Haematologica 88:538-46. 2003
    ..These effects could be useful in autoimmune diseases in order to interfere with the production of pathologic antibodies...
  13. ncbi request reprint Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients
    Alessandra Sperotto
    Division of Haematology, Bone Marrow Transplant Unit, Department of Medical and Morphological Research, University Hospital, Udine, Italy
    Adv Clin Path 6:77-85. 2002
    ..0% of patients submitted to ASCT with refractory disease can be potentially rescued by transplant...
  14. doi request reprint Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice
    Francesco Zaja
    Clinica Ematologica, DISM, Azienda Ospedaliero Universitaria S M Misericordia, Udine, Italy
    Am J Hematol 88:955-60. 2013
    ..These results confirm the activity and safety of bendamustine and rituximab combination even in patients with unfavorable clinical and biological features excluding del(17p)...
  15. ncbi request reprint Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells
    Salvatore De Vita
    University of Udine, Udine, Italy
    Arthritis Rheum 46:2029-33. 2002
    ..This study was undertaken to investigate the effects of B cell blockade in the treatment of refractory RA, and to evaluate the implications with regard to the role of B cells in the disease...
  16. ncbi request reprint B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia
    Francesco Zaja
    Clinica Ematologica, Policlinico Universitario, Udine, Italy
    Haematologica 87:189-95. 2002
    ..This could interfere with the production of autoantibodies in some immune diseases. The objective of this study was to assess the effects of rituximab in autoimmune hemolytic anemia and thrombocytopenia...
  17. ncbi request reprint The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery
    Francesca Patriarca
    Division of Haematology and Blood and Bone Marrow Transplantation Unit Carlo Melzi, Department of Clinical and Morphological Research, Udine, Italy
    Exp Hematol 34:389-96. 2006
    ....
  18. ncbi request reprint Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies
    Francesco Zaja
    Clinica Ematologica, Centro Trapianti e Terapie Cellulari Carlo Melzi, DISM, Azienda Ospedaliero Universitaria S M Misericordia, Udine, Italy
    Leuk Lymphoma 55:988-98. 2014
    ..This review considers available evidence on the management of relapsed/refractory MCL as discussed during a consensus meeting on the current treatment strategies for MCL. ..
  19. ncbi request reprint Rituximab for the treatment of type II mixed cryoglobulinemia
    Francesco Zaja
    Arthritis Rheum 46:2252-4; author reply 2254-5. 2002
  20. ncbi request reprint Efficacy and safety of rituximab in type II mixed cryoglobulinemia
    Francesco Zaja
    Division of Hematology Dipartimento di Ricerche Mediche e Morfologiche, University of Udine, Italy
    Blood 101:3827-34. 2003
    ..Rituximab may represent a safe and effective alternative to standard immunosuppression in type II MC. Controlled studies are needed to better define drug indications and the cost-efficacy profile in the different systemic manifestations...
  21. ncbi request reprint Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Italy
    J Clin Oncol 22:2654-61. 2004
    ..We performed a randomized comparative trial of FM with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) front-line chemotherapy with and without sequential rituximab...
  22. ncbi request reprint Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma
    Alessandro Rambaldi
    Divisione di Ematologia, Ospedali Riuniti Largo Barozzi 1, 24100, Bergamo, Italy
    Blood 105:3428-33. 2005
    ..006). RQ-PCR performed at presentation on BM samples predicts treatment response and long-term clinical outcome in patients with follicular lymphoma...
  23. ncbi request reprint Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings
    Mario B Regazzi
    Department of Pharmacology, Clinical Medicine IRCCS Policlinico San Matteo, Pavia, Italy
    Ther Drug Monit 27:785-92. 2005
    ..Because several studies reported an association between response and serum Rituximab concentrations, a treatment based on a pharmacokinetic model may be useful for predicting the desired drug concentration...
  24. ncbi request reprint Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination
    Luca Arcaini
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Viale Golgi 19, 27100 Pavia, Italy
    Oncologist 11:285-91. 2006
    ..This study describes the clinical features and the natural history of nongastric marginal-zone lymphomas and highlights that the dissemination to lymph nodes and bone marrow is associated with a poorer outcome...
  25. ncbi request reprint Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia
    Francesco Zaja
    Exp Hematol 34:571-2. 2006
  26. ncbi request reprint Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
    Andrea Gallamini
    Hematology Department, Ospedale Santa Croce, Cuneo, Italy
    Blood 110:2316-23. 2007
    ..This clinical trial was registered with the Osservatorio Nazionale sulla Sperimentazione cinica as ID no. 141202...
  27. ncbi request reprint Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma
    Alessandro Rambaldi
    Divisione di Ematologia, Ospedali Riuniti Bergamo, Largo Barozzi 1, 24100 Bergamo, Italy
    Blood 99:856-62. 2002
    ..001)...